Tactile Systems Technology, which does business as Tactile Medical, announced it has acquired LymphaTech Inc. for an upfront cash payment of $6.8 million, plus potential additional consideration tied to future milestone achievements. The transaction is aimed at expanding the company’s portfolio of solutions for lymphedema and strengthening its position in conditions associated with lymphatic dysfunction.
Based in Minneapolis and listed on Nasdaq under the ticker TCMD, Tactile Medical develops and markets at-home therapies for patients with chronic conditions, including lymphedema, lipedema, chronic venous insufficiency, and chronic inflammatory lung disease. The acquisition marks a strategic step in broadening its capabilities beyond device-based therapies into digital and connected care solutions.
Founded in 2014, LymphaTech, Inc. is a privately held medical technology company that has developed a digital, three-dimensional full body measurement and monitoring platform designed specifically for lymphedema. The condition, which results from damage to the lymphatic system and chronic fluid accumulation, can lead to swelling and tissue fibrosis, significantly affecting quality of life and increasing healthcare utilization.
LymphaTech’s primary technology is a handheld, clinically validated solution that uses proprietary algorithms and mobile scanning to generate highly accurate fluid volume and circumference measurements. The system produces a clinical-grade 3D model of the body and limbs, replacing traditional manual measurement methods that are often time-consuming and subject to variability. The platform also enables longitudinal surveillance, allowing clinicians to track swelling changes over time, including disease progression and response to treatment.
Beyond clinical measurement, the platform is used by compression garment manufacturers and fitters to digitize garment measurement and ordering. This functionality improves fit accuracy, reduces returns, and streamlines clinic workflows.
As part of the transaction, LymphaTech co-founders Mike Weiler, PhD, and Nate Frank, MBA, have joined Tactile Medical to help drive commercial adoption of the platform and support ongoing research initiatives. The company said the acquisition will also enhance its research and development capabilities, positioning it to advance next-generation lymphatic therapies and connected care solutions.
KEY QUOTES:
“This acquisition is a milestone in Tactile’s evolution from a product-based company to a comprehensive, integrated solutions leader for lymphatic dysfunction. By bringing together Tactile and LymphaTech, we become uniquely positioned to support patients and clinicians from early disease intervention to innovative connected therapies with long-term support and monitoring alongside our Kylee™ patient engagement application. The acquisition also brings advanced research competencies and programs that extend LymphaTech’s proprietary capabilities into next-generation approaches for assessment and treatment. As the scientific and clinical understanding of lymphatic dysfunction continues to increase, Tactile is poised to lead the next wave of technological innovation accelerating therapy for the 20 million symptomatic patients in the United States.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“With the rising prevalence of lymphedema, this tool is essential in providing clinicians with accurate, repeatable measurements that reduce variability and streamline workflows. By introducing greater objectivity and efficiency into assessment, it enhances confidence in clinical decision-making and enables providers to dedicate more time to patient care.”
Tony Gasparis, MD, Chief Medical Officer at Tactile Medical
